Click for a HEPATIQ free trial

2025 NEWS

April 11, 2025 - Go Beyond Fibrosis Staging

If you are attending Digestive Disease Week (DDW), May 4-6, 2025 in San Diego, please visit our booth 1511 for a free trial of HEPATIQ® - The Ultimate Liver Test®. Discover how HEPATIQ can take you beyond Fibrosis Staging to Physiologic Staging and provide you a full picture of the health of the liver. HEPATIQ is FDA cleared and insurance reimbursable.

Fibrosis tests estimate the extent of fibrosis, missing the compensatory effects of liver regeneration and increased blood flow to extant functioning tissue. HEPATIQ quantifies remaining liver function thus improving prediction of liver disease outcomes. To use a car analogy, other tests estimate the air in the gas tank. HEPATIQ measures the gas in the gas tank. HEPATIQ uses software to provide six indices of liver disease from a 20 minute low dose SPECT scan. It also provides a physiologic stage: H0 (normal) to H5 (transplant candidate). When fibrosis tests reach the “what now?” point, HEPATIQ provides more insight. Managing liver disease using fibrosis stage: F0 (normal) to F4 (cirrhosis) provides a partial view. An F4 or F3 patient may be H0 or H1 and may remain stable for years. On the other hand, another F4 or F3 patient may be H2 or H3 and at risk of decompensation. HEPATIQ can determine the liver’s physiologic stage and provide quantitative information on liver health. Given the limitations of fibrosis measurements, and quantitative liver function now available with HEPATIQ, we are at a turning point in liver disease management. Take advantage of the free trial to give it a try.

March 29, 2025 - Go beyond Child-Pugh scoring before an HCC intervention

If you are attending the Society of Interventional Radiology (SIR) 2025 Annual Scientific Meeting in Nashville, please visit our booth 324 to learn how HEPATIQ® - The Ultimate Liver Test® - can take you beyond Child-Pugh (CP) scoring and provide you a full picture of the health of the liver. HEPATIQ is FDA cleared and insurance reimbursable. Liver transplantation (LT) has the greatest cure potential for hepatocellular carcinoma (HCC) patients. Bridge therapies prior to LT include stereotactic body radiation therapy (SBRT), Yttrium-90 radioembolization (Y90), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and surgical resection. Child-Pugh (CP) score is often used in treatment decision making. However it is a categorical score which is partly subjective. It is not a quantitative index of remaining liver function. The CP score is determined by assigning points to two liver disease complications (encephalopathy and ascites), and three lab test results (Bilirubin, Albumin and Prothrombin Time/INR). Each of these five factors are assigned a score of 1 to 3 points. The total points determine the CP category: A - Good hepatic function (5-6 points), B - Moderately impaired hepatic function (7-9 points), and C - Advanced hepatic dysfunction (10-15 points). HEPATIQ provides an objective quantitative index (PHM) of remaining liver function and a physiologic stage H0 to H5. PHM outperforms Bilirubin, Albumin and INR in identifying compensated liver disease patients who will likely do well after an intervention despite their liver disease (www.hepatiq.com/publications). We are offering new customers a 3 month free trial of up to 30 HEPATIQ reports worth $2,850. There is no obligation to buy after the free trial. HEPATIQ uses SPECT imaging to provide physicians with quantitative liver function data not available from any other technique - blood tests, elastography (ultrasound or MR), or even a biopsy. HEPATIQ is pure software and uses existing equipment, radioisotope, infrastructure and staff. No capital investment is needed.

February 17, 2025 - Use HEPATIQ to better predict chronic liver disease outcomes

If you are attending the Global Hepatitis Summit (GHS), Mar 18-20 in Los Angeles, please visit our booth G3 to learn how HEPATIQ® - The Ultimate Liver Test™ - can help you take care of chronic liver disease patients better than traditional liver tests. We are offering new customers a 3 month free trial of up to 30 HEPATIQ reports worth $2,850. There is no obligation to buy after the free trial. HEPATIQ uses SPECT imaging to provide physicians with quantitative liver function data not available from any other technique - blood tests, elastography (ultrasound or MR), or even a biopsy. HEPATIQ is pure software and uses existing equipment, radioisotope, infrastructure and staff. No capital investment is needed.

The HEPATIQ indices can indicate both liver decompensation and recompensation as the two case studies below illustrate. Case Study 1: Liver Decompensation - H2 cryptogenic cirrhotic progressed to H5 and died.74 year old female presented as H2 cirrhotic. Over the next 4 years her PHM and fLV both decreased indicating progressive chronic liver disease. There was no indication of alcoholic hepatitis. She progressed to H4 and developed ascites. She died as an H5 while awaiting a transplant.

Case Study 2: Liver Recompensation - H5 improved to H2 after autoimmune hepatitis treated. 65 year old female presented with ascites and jaundice. PHM was about 59 (H5). She was diagnosed with Autoimmune Chronic Active Hepatitis and treated with Prednisone/Imuran. PHM improved to 80 (H3) in a few months and eventually to 93 (H2)

Predictive ability of blood test based scoring systems, such as APRI, FIB-4, NFS, etc., to identify persons with advanced fibrosis associated with development of cirrhosis is modest [B]. Fibrosis scores have poor sensitivity for predicting advanced liver disease in diabetic patients [C]. Elastography or a biopsy may be performed for staging liver disease (F0-F4) but they don't provide information on liver functional reserve. It may be beneficial to use HEPATIQ to assess liver functional reserve for patients designated as abnormal (>F0) [12,13,17,22]. Furthermore, before a liver surgery or any liver interventional procedure, use HEPATIQ to assess liver functional reserve [D].

January 2, 2025 - Before an intervention, individually assess liver functional reserve

If you are attending the Society of Interventional Oncology (SIO) conference Jan 31 – Feb 2 in Las Vegas, please visit our booth 107 to learn more about HEPATIQ® - The Ultimate Liver Test™. We are offering new customers a 3 month free trial of up to 30 HEPATIQ reports worth $2,850. There is no obligation to buy after the free trial.
A 2022 publication in the Journal of Hepatology, The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma, by D’Avola et al [D], states that “Patients with compensated cirrhosis and large liver functional reserve can always receive the most radical treatment”. However, “a more detailed and individualized assessment should be carried out in patients with poorer liver functional reserve”. The HEPATIQ® test’s PHM (perfused hepatic mass) and fLV (functional liver volume) indices provide a measure of the liver functional reserve.[7,11,13,14,15,18,19,20,22,24,28]

Case Study: The case for individualized assessments is illustrated here by the HEPAVIEW™ images shown for an 82 year old female cirrhotic patient who developed hepatocellular carcinoma (HCC) and later died.

As the HEPATIQ fLV-PHM differential graph below shows, when she was first assessed for liver function she was an H2. After her HCC was detected, she was treated with radio frequency ablation and then with Y90 radio embolization. She had progressed to H4 by the time she was treated with Y90. She developed ascites, hepatic encephalopathy and subsequently died.

2024 news

BACK

NEXT